research papers\(\def\hfill{\hskip 5em}\def\hfil{\hskip 3em}\def\eqno#1{\hfil {#1}}\)

Journal logoSTRUCTURAL
BIOLOGY
ISSN: 2059-7983

Conformational transition of the Ixodes ricinus salivary serpin Iripin-4

crossmark logo

aDepartment of Chemistry, University of South Bohemia in České Budějovice, 370 05 České Budějovice, Czech Republic, bDepartment of Medical Biology, Faculty of Science, University of South Bohemia in České Budějovice, 370 05 České Budějovice, Czech Republic, and cInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences, 370 05 České Budějovice, Czech Republic
*Correspondence e-mail: chmelar@jcu.cz, ivanaks@seznam.cz

Edited by K. Djinovic-Carugo, EMBL Grenoble, France (Received 16 June 2022; accepted 9 March 2023; online 24 April 2023)

Iripin-4, one of the many salivary serpins from Ixodes ricinus ticks with an as-yet unexplained function, crystallized in two different structural conformations, namely the native partially relaxed state and the cleaved serpin. The native structure was solved at a resolution of 2.3 Å and the structure of the cleaved conformation was solved at 2.0 Å resolution. Furthermore, structural changes were observed when the reactive-centre loop transitioned from the native conformation to the cleaved conformation. In addition to this finding, it was confirmed that Glu341 represents a primary substrate-recognition site for the inhibitory mechanism. The presence of glutamate instead of the typical arginine in the P1 recognition site of all structurally characterized I. ricinus serpins (PDB entries 7b2t, 7pmu and 7ahp), except for the tyrosine in the P1 site of Iripin-2 (formerly IRS-2; PDB entry 3nda), would explain the absence of inhibition of the tested proteases that cleave their substrate after arginine. Further research on Iripin-4 should focus on functional analysis of this interesting serpin.

1. Introduction

Ixodes ricinus (subclass Acari, order Ixodidae) is one of the most important European vectors, transmitting many pathogens, and is therefore also of veterinary and medical importance. This hard tick species attacks many cold- and warm-blooded vertebrate hosts, including humans. The two most commonly reported tick-borne infections in humans are Lyme disease caused by Borrelia burgdorferi sensu lato and the Western European subtype of tick-borne encephalitis virus, of which I. ricinus is the main vector in Europe (Rizzoli et al., 2011[Rizzoli, A., Hauffe, H. C., Carpi, G., Vourc'h, G. I., Neteler, M. & Rosà, R. (2011). Euro Surveill. 16, 19906.]; Madison-Antenucci et al., 2020[Madison-Antenucci, S., Kramer, L. D., Gebhardt, L. L. & Kauffman, E. (2020). Clin. Microbiol. Rev. 33, e00083-18.]; Boulanger et al., 2019[Boulanger, N., Boyer, P., Talagrand-Reboul, E. & Hansmann, Y. (2019). Med. Mal. Infect. 49, 87-97.]).

As I. ricinus is widespread in Europe, efforts have been made to reduce tick abundance and thus reduce the risk of possible infection. One way to reduce tick numbers is to use acaricides, but ticks can develop resistance to these products in the long term. Another strategy is to use repellents, which often contain toxic substances that can cause environmental contamination, which has become a serious problem. Moreover, repellents provide only short-term protection (Rosario-Cruz et al., 2009[Rosario-Cruz, R., Almazan, C., Miller, R. J., Dominguez-Garcia, D. I., Hernandez-Ortiz, R. & de La Fuente, J. (2009). Front. Biosci. 14, 2657-2665.]). A biological approach to tick control, such as vaccinating the host, appears to be the most viable option. This approach can induce protective host immunity, leading to host rejection of the tick. Tick saliva contains many important substances that could be crucial for developing a vaccine to block transmission of these substances. Serine protease inhibitors (serpins) have been tested in several studies, and recombinant serpins from several tick species have been described as candidates for vaccine design (de la Fuente et al., 2016[Fuente, J. de la, Kopáček, P., Lew-Tabor, A. & Maritz-Olivier, C. (2016). Parasite Immunol. 38, 754-769.]). For example, an I. ricinus serpin called Iris induced protective immunity against nymphs and adults fed on vaccinated rabbits but not against nymphs fed on mice (Prevot et al., 2007[Prevot, P.-P., Couvreur, B., Denis, V., Brossard, M., Vanhamme, L. & Godfroid, E. (2007). Vaccine, 25, 3284-3292.]; Meekins et al., 2017[Meekins, D. A., Kanost, M. R. & Michel, K. (2017). Semin. Cell Dev. Biol. 62, 105-119.]).

With more than 6000 members, serpins are among the largest families of protease inhibitors. They are widespread in all organisms and function in many physiological processes (Silverman et al., 2010[Silverman, G. A., Whisstock, J. C., Bottomley, S. P., Huntington, J. A., Kaiserman, D., Luke, C. J., Pak, S. C., Reichhart, J. M. & Bird, P. I. (2010). J. Biol. Chem. 285, 24299-24305.]; Spence et al., 2021[Spence, M. A., Mortimer, M. D., Buckle, A. M., Minh, B. Q. & Jackson, C. J. (2021). Mol. Biol. Evol. 38, 2915-2929.]). Serpins differ from other groups of protease inhibitors mainly in their unique mode of inhibition. To inhibit the target protease, serpins undergo a fundamental conformational change that leads to inactivation of both the protease and the serpin itself. For this reason, serpins are referred to as `one use only' or `suicide' inhibitors (Whisstock et al., 1998[Whisstock, J., Skinner, R. & Lesk, A. M. (1998). Trends Biochem. Sci. 23, 63-67.]; Dunstone & Whisstock, 2011[Dunstone, M. A. & Whisstock, J. C. (2011). Methods Enzymol. 501, 63-87.]). Many serpins have functions other than those implied by their name. There is ample evidence that some serpins, such as the viral CrmA and plant serpin 1, can inhibit cysteine proteases in addition to serine proteases (Komiyama et al., 1994[Komiyama, T., Ray, C. A., Pickup, D. J., Howard, A. D., Thornberry, N. A., Peterson, E. P. & Salvesen, G. (1994). J. Biol. Chem. 269, 19331-19337.]; Vercammen et al., 2006[Vercammen, D., Belenghi, B., van de Cotte, B., Beunens, T., Gavigan, J.-A., De Rycke, R., Brackenier, A., Inzé, D., Harris, J. L. & Van Breusegem, F. (2006). J. Mol. Biol. 364, 625-636.]). The serpin family also contains non-inhibitory members with roles in, for example, hormone transport, protein folding, blood-pressure regulation, chromatin condensation and tumour progression (Kaiserman et al., 2006[Kaiserman, D., Whisstock, J. C. & Bird, P. I. (2006). Expert Rev. Mol. Med. 8, 1-19.]).

The main structural feature of all serpins is a conserved tertiary structure consisting of a core domain of ∼350 amino acids. Thus, the secondary structure of serpins consists of three β-sheets (β-sheets A, B and C), at least eight α-helices (A–H) and a reactive-centre loop (RCL) (Gettins, 2002[Gettins, P. G. W. (2002). Chem. Rev. 102, 4751-4804.]). The amino acids in the RCL, particularly the residues at the P1 and P1′ positions, determine the protease selectivity of serpins by mimicking the substrate of the target protease (Sanrattana et al., 2019[Sanrattana, W., Maas, C. & de Maat, S. (2019). Front. Med. 6, 25.]). Numerous crystallographic studies have provided a large amount of structural data on possible conformations of serpins that may be independent of the inhibition process. The conformations can be divided into a series of monomeric serpin structures (native fully stressed state, native partially relaxed state, latent conformation, abnormal δ-conformation and cleaved conformation) and protease-inhibited complexes (Michaelis–Menten complex and covalent complex) (Dunstone & Whisstock, 2011[Dunstone, M. A. & Whisstock, J. C. (2011). Methods Enzymol. 501, 63-87.]).

The mechanism of protease inhibition has been well explained, as all inhibitory serpins undergo a similar molecular process that is required for protease inhibition. This process begins with recognition of the exposed RCL of the native metastable serpin by the protease as a `substrate' and the formation of a Michaelis–Menten complex. Subsequently, the RCL is cleaved by the protease between the P1 and P1′ sites, resulting in binding of the protease to the RCL; the protease is then transported to the other side of the serpin by the RCL. This transition of the serpin to the more thermally stable conformation is related to insertion of the RCL into β-sheet A as an additional β-strand and simultaneous inactivation of the serpin and the protease by the formation of a covalent complex. If the reaction does not proceed sufficiently rapidly, the process results in an inactivated serpin in its most thermally stable cleaved conformation and a released active protease (Dunstone & Whisstock, 2011[Dunstone, M. A. & Whisstock, J. C. (2011). Methods Enzymol. 501, 63-87.]; Huntington & Carrell, 2001[Huntington, J. A. & Carrell, R. W. (2001). Sci. Prog. 84, 125-136.]; Huntington, 2011[Huntington, J. A. (2011). J. Thromb. Haemost. 9, 26-34.]). The inhibition process represents a flexible structural change that can make serpins vulnerable to mutations. Such mutations can lead to pathological conditions called serpinopathies, which manifest as thrombosis, cirrhosis, emphysema, immune hypersensitivity and other diseases that result from serpin dysfunction (Whisstock et al., 2010[Whisstock, J. C., Silverman, G. A., Bird, P. I., Bottomley, S. P., Kaiserman, D., Luke, C. J., Pak, S. C., Reichhart, J. M. & Huntington, J. A. (2010). J. Biol. Chem. 285, 24307-24312.]).

To fully understand tick serpins and their functions, it is necessary to uncover structural information about individual serpins and their complexes with proteases. This may represent an essential starting point for the design and development of new drugs. Therefore, X-ray crystallography was used to solve the structure of the I. ricinus serpin Iripin-4 in its original native conformation; the cleaved conformation represents the resulting failed inhibition.

2. Materials and methods

2.1. Protein cloning, expression and purification

A full-length cDNA sequence of the gene that encodes Iripin-4 was obtained from the salivary glands of female I. ricinus ticks fed on guinea pigs by reverse transcription using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Penzberg, Germany) during a salivary-gland transcriptome project (Schwarz et al., 2013[Schwarz, A., von Reumont, B. M., Erhart, J., Chagas, A. C., Ribeiro, J. M. C. & Kotsyfakis, M. (2013). FASEB J. 27, 4745-4756.]). Iripin-4 was amplified using the primers shown in Supplementary Table S1, cloned into a Champion pET-SUMO expression vector (Life Technologies, Carlsbad, California, USA) using NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs, Ipswich, Massachusetts, USA) and transformed into Escherichia coli Rosetta 2 (DE3) pLysS competent cells (Novagen, Merck Life Science, Darmstadt, Germany). An overnight culture (10 ml l−1) was inoculated into autoinduction TB medium (100 µg ml−1 kanamycin, 34 µg ml−1 chloramphenicol) and incubated for 24 h at 25°C. Bacterial cells were then harvested and disrupted with a cell disruptor. Soluble SUMO-tagged Iripin-4 was purified using a HisTrap FF column (GE Healthcare, Chicago, Illinois, USA) and eluted with 200 mM imidazole. After the first purification, the His and SUMO tags were cleaved using SUMO protease [1:100(w/w)] overnight at laboratory temperature. Samples were then reloaded onto a HisTrap column to separate the tags from native serpin. This step was followed by ion-exchange chromatography using a HiTrap Q HP column (GE Healthcare), which ensured sufficient protein purity. The final protein concentration was 1.17 mg ml−1 in 20 mM Tris pH 7.4, 20 mM NaCl and the protein was stored at −80°C.

2.2. Analysis of complex formation of Iripin-4 with proteases

The formation of covalent complexes of Iripin-4 was performed as reported previously (Chmelar et al., 2011[Chmelar, J., Oliveira, C. J., Rezacova, P., Francischetti, I. M. B., Kovarova, Z., Pejler, G., Kopacek, P., Ribeiro, J. M. C., Mares, M., Kopecky, J. & Kotsyfakis, M. (2011). Blood, 117, 736-744.]). Selected serine proteases (trypsin, thrombin, fXa, APC, fXIa, plasmin and elastase) were incubated with equimolar amounts of Iripin-4 for 1 h at laboratory temperature (final concentration of 1 µM). Serpin–protease complex formation was analysed on reducing SDS–PAGE using 12% gels followed by Coomassie staining. The second-order inhibition rate constants for native Iripin-4 against recombinant human granzyme B were then defined as described in Chmelar et al. (2011[Chmelar, J., Oliveira, C. J., Rezacova, P., Francischetti, I. M. B., Kovarova, Z., Pejler, G., Kopacek, P., Ribeiro, J. M. C., Mares, M., Kopecky, J. & Kotsyfakis, M. (2011). Blood, 117, 736-744.]). In order to detect substrate hydrolysis while avoiding saturation of the reaction, the concentration used was chosen based on the biochemical properties of granzyme B. Thus, one unit of granzyme B hydrolyzes 1 pmol min−1 Ac-IEPD-pNA substrate (200 µM) at 37°C. The assay was performed in triplicate at 37°C and stopped at each time point by addition of the aforementioned substrate. Prior to substrate addition, Iripin-4 was pre-incubated with granzyme B for 0–14 min at a protease concentration of 1 U µl−1 (0.2 U µl−1 final concentration). The assay was measured at five different concentrations of Iripin-4 and plotted against the serpin concentration. The slope of the line of best fit provided an estimate of the second-order rate constant. An appropriate buffer consisting of 20 mM Tris pH 7.4, 150 mM NaCl, 0.01% Triton X-100 was used. The rate of substrate hydrolysis was measured using a plate reader (BioTek Synergy H1 Plate Reader, USA; absorbance at 405 nm) in a 96-well plate.

2.3. Protein crystallization, X-ray data collection and processing

A suitable protein concentration for crystallization screening was determined using the Pre-Crystallization Test (PCT; Hampton Research, Aliso Viejo, California, USA). Crystallization experiments were performed using the sitting-drop vapour-diffusion technique in 96-well Swissci MRC 2-drop or 3-drop crystallization plates (Molecular Dimensions, Newmarket, Suffolk, United Kingdom). Initial screening of crystallization conditions and further crystallization experiments were carried out using an OryxNano crystallization robot (Douglas Instruments, Hungerford, United Kingdom). Commercially available crystallization kits (Crystal Screen, PEGRx, PEG/Ion and Index from Hampton Research and JBScreen JCSG++ from Jena Bioscience) were used to screen for crystallization conditions. Protein solution:well solution ratios of 1:0.5 and 1:1 (0.4:0.2 µl and 0.4:0.4 µl) were used with protein concentrations of 1.17 and 2.3 mg ml−1 and the drop solution was equilibrated against 50 µl reservoir solution at 4°C. Suitable crystallization conditions were identified as JBScreen JCSG++ conditions H8 [25%(w/v) PEG 3350, 0.1 M bis-Tris pH 5.5, 0.2 M sodium chloride] and H10 [25%(w/v) PEG 3350, 0.1 M bis-Tris pH 5.5, 0.2 M ammonium acetate]. A simple 2D gradient was used for these conditions to optimize the crystal quality in a larger volume (0.5:0.5 µl).

For data collection, both native and cleaved Iripin-4 crystals were mounted directly from the crystallization drop and flash-cooled in liquid nitrogen without further cryoprotection prior to measurements. Diffraction data were collected on BL14.1 at the BESSY II electron-storage ring operated by Helmholtz-Zentrum Berlin (Mueller et al., 2015[Mueller, U., Förster, R., Hellmig, M., Huschmann, F. U., Kastner, A., Malecki, P., Pühringer, S., Röwer, M., Sparta, K., Steffien, M., Ühlein, M., Wilk, P. & Weiss, M. S. (2015). Eur. Phys. J. Plus, 130, 141.]). Data for all crystals were processed using XDS (Kabsch, 2010[Kabsch, W. (2010). Acta Cryst. D66, 125-132.]) with the XDSAPP graphical user interface (Sparta et al., 2016[Sparta, K. M., Krug, M., Heinemann, U., Mueller, U. & Weiss, M. S. (2016). J. Appl. Cryst. 49, 1085-1092.]). The solvent content of the crystal was analysed with MATTHEWS_COEF from the CCP4 suite (Winn et al., 2011[Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson, K. S. (2011). Acta Cryst. D67, 235-242.]) Data-collection statistics for both data sets are summarized in Table 1[link].

Table 1
X-ray data-collection and refinement statistics

Values in parentheses are for the highest resolution shell.

  Native Iripin-4 Cleaved Iripin-4
Data collection
 X-ray diffraction source BL14.2, BESSY II, Germany BL14.2, BESSY II, Germany
 Wavelength (Å) 0.9184 0.9184
 Temperature (K) 100 100
 Detector PILATUS 6M PILATUS 6M
 Crystal-to-detector distance (mm) 175.66 373.61
 Rotation range per image (°) 0.10 0.10
 Total rotation range (°) 270.00 360.00
 Exposure time per image (s) 0.10 0.10
 Resolution range (Å) 44.61–2.30 (2.44–2.30) 46.42–2.00 (2.12–2.00)
 Space group P3121 [No. 152] P21 [No. 4]
 Molecules in asymmetric unit 1 4
a, b, c (Å) 78.93, 78.93, 117.78 65.70, 138.41, 80.22
α, β, γ (°) 90.00, 90.00, 120.00 90.00, 107.70, 90.00
 Mosaicity (°) 0.105 0.128
 Total No. of reflections 289932 (43011) 634544 (98469)
 No. of unique reflections 19373 (3085) 91690 (14692)
 Multiplicity 14.97 6.92
 Average I/σ(I) 22.47 (4.30) 9.10 (2.32)
 Completeness (%) 99.70 (99.70) 99.40 (98.60)
 CC1/2 99.90 (79.70) 99.70 (77.30)
Rmeas (%) 9.60 (62.40) 16.70 (85.30)
 Overall B factor from Wilson plot (Å2) 39.20 23.00
Refinement
 Resolution range (Å) 44.62–2.30 46.42–2.00
 No. of reflections in working set 18404 89590
 Final R/Rfree§ (%) 20.30/25.40 19.30/25.30
 Mean B value (Å2) 39.80 28.00
 No. of atoms in the asymmetric unit
  Protein 2962 11869
  Ligand: chloride ion   4
  Ligand: nickel ion 1  
  Water 196 1276
  Total 3168 13196
 R.m.s. deviations
  Bond lengths (Å) 0.007 0.007
  Angles (°) 1.444 1.455
 Average B factors, overall (Å2) 42.0 28.0
 Ramachandran plot
  Most favoured (%) 95.99 98.17
  Allowed (%) 4.01 1.83
MolProbity score 1.46 [99th percentile] 1.27 [99th percentile]
 PDB code 7zbf 7zas
Rmeas = [\textstyle \sum_{hkl}\{N(hkl)/[N(hkl)-1]\}^{1/2}\sum_{i}|I_{i}(hkl)- \langle I(hkl)\rangle|/][\textstyle \sum_{hkl}\sum_{i}I_{i}(hkl)], where the average intensity 〈I(hkl)〉 is taken over all symmetry-equivalent measurements and I(hkl) is the measured intensity for any given reflection.
R = [\textstyle \sum_{hkl}\big ||F_{\rm obs}|-|F_{\rm calc}|\big |/][\textstyle \sum_{hkl}|F_{\rm obs}|], where Fobs and Fcalc are the observed and calculated structure factors, respectively.
§Rfree is equivalent to R but is calculated for 1.87% of the reflections chosen at random and omitted from the refinement process.
¶The 100th percentile is the best among structures of comparable resolution; the 0th percentile is the worst.

2.4. Structure determination and refinement

The structures of Iripin-4 were solved using the CCP4 suite (Winn et al., 2011[Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson, K. S. (2011). Acta Cryst. D67, 235-242.]). The MOLREP (Vagin & Teplyakov, 2010[Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22-25.]) molecular-replacement method using MrBUMP, an automated pipeline for molecular replacement (Krissinel et al., 2018[Krissinel, E., Uski, V., Lebedev, A., Winn, M. & Ballard, C. (2018). Acta Cryst. D74, 143-151.]), was used for the cleaved conformation, and the structure of Iripin-2 (PDB entry 3nda; Chmelar et al., 2011[Chmelar, J., Oliveira, C. J., Rezacova, P., Francischetti, I. M. B., Kovarova, Z., Pejler, G., Kopacek, P., Ribeiro, J. M. C., Mares, M., Kopecky, J. & Kotsyfakis, M. (2011). Blood, 117, 736-744.]), with 56.5% sequence identity, generated by an automated model search using the BALBES molecular-replacement pipeline (Long et al., 2008[Long, F., Vagin, A. A., Young, P. & Murshudov, G. N. (2008). Acta Cryst. D64, 125-132.]) was used for the native conformation. The resolution cutoff for native Iripin-4 was 2.3 Å due to the presence of two ice rings at 2.25 and 1.95 Å resolution. The structures were refined using REFMAC5 (Murshudov et al., 2011[Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355-367.]) from the CCP4 package (Winn et al., 2011[Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson, K. S. (2011). Acta Cryst. D67, 235-242.]) and were manually rebuilt in Coot (Emsley et al., 2010[Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486-501.]) based on evaluation of the electron-density peaks. Improvement during refinement was monitored by structure validation throughout the refinement process. Water molecules were added to the model using the REFMAC5 interface. The accepted solvent molecules had hydrogen-bond contacts with permissible geometry in the range 2.5–3.5 Å to protein atoms or to existing solvent. At this point, residues and water molecules with two possible conformations were included, and their alternative conformations were added for further refinement. In the final refinement steps, the Ni2+ ion (native structure) and four chloride ions (cleaved structure) were incorporated into the respective (2FoFc) and (FoFc) electron-density maps using coordinates from the ligand data bank in Coot (Emsley et al., 2010[Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486-501.]). The MolProbity server (Chen et al., 2010[Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12-21.]) and the wwPDB OneDep validation system (Young et al., 2017[Young, J. Y., Westbrook, J. D., Feng, Z., Sala, R., Peisach, E., Oldfield, T. J., Sen, S., Gutmanas, A., Armstrong, D. R., Berrisford, J. M., Chen, L., Chen, M., Di Costanzo, L., Dimitropoulos, D., Gao, G., Ghosh, S., Gore, S., Guranovic, V., Hendrickx, P. M. S., Hudson, B. P., Igarashi, R., Ikegawa, Y., Kobayashi, N., Lawson, C. L., Liang, Y., Mading, S., Mak, L., Mir, M. S., Mukhopadhyay, A., Patwardhan, A., Persikova, I., Rinaldi, L., Sanz-Garcia, E., Sekharan, M. R., Shao, C., Swaminathan, G. J., Tan, L., Ulrich, E. L., van Ginkel, G., Yamashita, R., Yang, H., Zhuravleva, M. A., Quesada, M., Kleywegt, G. J., Berman, H. M., Markley, J. L., Nakamura, H., Velankar, S. & Burley, S. K. (2017). Structure, 25, 536-545.]) were used for final qualitative model validation. All figures were created by PyMOL (Schrödinger) or CCP4mg (Mc­Nicholas et al., 2011[McNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. M. (2011). Acta Cryst. D67, 386-394.]). To visualize the cleaved conformation, chain C was used. The refinement statistics are summarized in Table 1[link].

3. Results

3.1. Recombinant Iripin-4 production and purification

The Iripin-4 gene transcript amplified from tick cDNA showed three amino-acid substitutions, H78Q, G155E and G307D, compared with the deposited Iripin-4 sequence (GADI01002650; Supplementary Fig. S1) used for primer design. This is not an artefact but is most likely to be the result of high inter-tick variability in the genes expressed in salivary glands, as reported in Kotál et al. (2021[Kotál, J., Polderdijk, S. G. I., Langhansová, H., Ederová, M., Martins, L. A., Beránková, Z., Chlastáková, A., Hajdušek, O., Kotsyfakis, M., Huntington, J. A. & Chmelař, J. (2021). Int. J. Mol. Sci. 22, 9480.]). The resulting protein has no substitutions in the RCL or the hinge region, and therefore should retain the same inhibitory function and specificity. The final yield of Iripin-4 was 17 mg (∼2 mg per litre of medium), which is a sufficient concentration for further experiments (Supplementary Fig. S2). Using the NetNGlyc 1.0 and NetOGlyc 4.0 servers, the amino-acid sequence of Iripin-4 was estimated to contain two potential N-glycosylation sites [N-X-(S/T)] and four potential O-glycosylation sites (Supplementary Table S2).

3.2. Complex formation of Iripin-4 with proteases

Iripin-4 is not a suitable inhibitor of the selected serine proteases. No complex formation was observed between Iripin-4 and any of the tested serine proteases. In addition, Iripin-4 acted as a substrate for porcine elastase, as can be observed as a double band on a NuPAGE gel corresponding to native and cleaved serpin (Fig. 1[link]). For this reason the second-order rate constant for Iripin-4 inhibition of granzyme B was determined (Fig. 2[link]). Granzyme B is a component of cytolytic granules produced by natural killer and cytotoxic T lymphocytes. Granzyme B serves as a mediator of inflammation, controls the coagulation cascade (the ability to trigger inflammatory cytokines) and has proteolytic activity that is crucial for programmed cell death (Garzón-Tituaña et al., 2020[Garzón-Tituaña, M., Arias, M. A., Sierra-Monzón, J. L., Morte-Romea, E., Santiago, L., Ramirez-Labrada, A., Martinez-Lostao, L., Paño-Pardo, J. R., Galvez, E. M. & Pardo, J. (2020). Front. Immunol. 11, 1054.]). Iripin-4 protects cells by inhibiting granzyme B, and is also partly responsible for prolonging the attachment of the tick to the host. Mutants of Iripin-4 show similar but insignificant activity towards native Iripin-4 (data not shown).

[Figure 1]
Figure 1
Analysis of heat-stable complex formation between Iripin-4 and tested proteases. No complex formation was observed. There is visible cleavage of Iripin-4 by porcine elastase, as shown by a black arrow. Proteins were resolved on 12% NuPAGE Bis-Tris gels and visualized by Coomassie staining.
[Figure 2]
Figure 2
The relationship between Iripin-4 concentration and kobs, the observed second-order rate constant for the binding of human granzyme B to Iripin-4. kobs was determined using a para-nitroanilide substrate (Ac-IEPD-pNA).

3.3. Crystallization of Iripin-4 conformations

Based on initial screening, several successful crystallization conditions were found at both protein concentrations. Preliminary data collection indicated that optimization of crystallization was required, and therefore a protein concentration of 1.17 mg ml−1 with a larger drop volume (2 µl) was used for further optimization. Crystals of native Iripin-4 grew under conditions consisting of 25%(w/v) PEG 3350, 0.1 M bis-Tris pH 5.5, 0.2 M ammonium acetate (Supplementary Fig. S3). The difference in the crystallization conditions for the cleaved conformation was the presence of 0.2 M sodium chloride instead of 0.2 M ammonium acetate as used in the crystallization of the native serpin (Supplementary Fig. S4). One of the most likely reasons for obtaining crystals of both conformations was the storage time of the protein sample. In the case of native Iripin-4 the protein sample was freshly obtained, whereas the crystals of cleaved Iripin-4 were formed from a protein sample that had been stored at −20°C for six months before optimization was initiated.

3.4. The partially relaxed state of the native conformation

The structure of native Iripin-4 was solved at 2.3 Å resolution and the crystal belonged to space group P3121 (No. 152), with unit-cell parameters a = 77.78, b = 77.78, c = 109.49 Å, α = 90.0, β = 90.0, γ = 120.0°. The crystal contained one molecule in the asymmetric unit with 51.33% solvent content and a Matthews coefficient of 2.53 Å3 Da−1. Detailed refinement statistics are given in Table 1[link].

The overall structure of Iripin-4 consists of all 376 residues with a typical fold of native serpin secondary structure with the RCL exposed on top of β-sheet C as a protease `bait (substrate)' (Fig. 3[link]; Huntington, 2011[Huntington, J. A. (2011). J. Thromb. Haemost. 9, 26-34.]). The structure consists of nine α-helices and three β-sheets (A, B and C) arranged sequentially in the order αA–β1–αB–αC–αD–β2–αE–β3–αF–β4–β5–β6–β7–β8–αG–αH–β9–β10–αI–β11–β12–β13–β14 (Fig. 4[link]b). β-Sheet A consists of five β-strands, β-sheet B of five β-strands and β-sheet C of four β-strands. The crystal structure has a tentatively assigned nickel cation (Ni2+) located between two molecules of Iripin-4 with crystallographic symmetry that interacts with His253 and Asp257 of both molecules (Supplementary Fig. S5). The presence of the Ni2+ ion, which was the most logical choice, is probably due to release of this ion during affinity purification.

[Figure 3]
Figure 3
The RCL of native Iripin-4. (a) Front view of the RCL (blue) showing the inserted residues into β-sheet A (cyan) and highly flexible residues of the hinge region of the RCL (purple). (b) View rotated by 50°.
[Figure 4]
Figure 4
Crystal structures of Iripin-4. (a) Native Iripin-4; the position of the RCL partially inserted into the breach region of β-sheet A is highlighted. (b) Side view of the native conformation. (c) Cleaved Iripin-4 displaying an additional β-strand in β-sheet A as a result of RCL insertion. (d) Side view of the cleaved conformation. Both crystal structures are displayed as cartoons; β-sheet A is in cyan and the RCL is in blue. The position of the P1 cleavage site is marked by a blue asterisk.

The crystal structure of Iripin-4 shows the typical partially relaxed state of native serpins, in which the RCL, which is located between β-sheet A and β-sheet C, is partially inserted into the breach region (Fig. 4[link]a; the top part of β-sheet A; Whisstock & Bottomley). In contrast, the remaining part of the RCL is exposed (Fig. 4[link]b). This state is likely to be the result of a crystallization process that trapped the serpin in one of two possible states, given the high flexibility of the RCL and the dynamic equilibrium between the partially inserted and the fully exposed native state. The six amino acids Ala326, Gly327, Thr328, Glu329, Ala330 and Ala331 are inserted between the third β-strand (s3A) and the fifth β-strand (s5A) of β-sheet A (Fig. 3[link]). Three amino acids in the exposed part of the RCL, namely Thr334 and Gly335, which are part of the hinge region, and Leu343, were modelled into the structure despite the lower electron density observed here, indicating high flexibility of these two regions of the RCL (Fig. 3[link]).

3.5. Structural transition to the cleaved conformation

The crystal of cleaved Iripin-4 diffracted to 2.00 Å resolution and belonged to space group P21 (No. 4), with unit-cell parameters a = 65.70, b = 138.41, c = 80.22 Å, α = 90.0, β = 107.7, γ = 90.0°. The crystal contains four molecules in the asymmetric unit, with a solvent content of 40.65% and a Matthews coefficient of 2.07 Å3 Da−1. Detailed refinement statistics are given in Table 1[link].

The structure of the cleaved conformation consists of a typical mixed αβ secondary serpin structure with an N-terminal helical region and a C-terminal β-sheet fold. The overall structure consists of nine α-helices (A–I) and three β-sheets arranged sequentially in the order αA–β1–αB–αC–αD–β2–αE–β3–αF–β4–β5–β6–β7–β8–αG–αH–β9–β10–αI–β11–β12–β13–β14–β15 (Fig. 4[link]c). The additional β12 strand results from the insertion of an RCL between the two β-strands of β-sheet A to form an additional strand called s4A; more precisely, it is located between the β11 strand (s5A) and the β4 strand (s3A) (Fig. 4[link]d). A chloride ion (Cl) is present in the model at the same position in all chains and interacts with Leu215 in the gate region. The gate region (Fig. 5[link]) is responsible for stabilizing the RCL and preventing its premature insertion into β-sheet A (Irving et al., 2015[Irving, J. A., Miranda, E., Haq, I., Perez, J., Kotov, V. R., Faull, S., Motamedi-Shad, N. & Lomas, D. A. (2015). Biochem. J. 468, 99-108.]).

[Figure 5]
Figure 5
Structural superposition of Iripin-4 conformations. The native Iripin-4 (cyan) with an exposed RCL (blue) is aligned with cleaved Iripin-4 (grey) containing a new additional β-strand (marine) labelled s4A. The three regions responsible for insertion of the RCL into β-sheet A are marked in circles (Khan et al., 2011[Khan, M. S., Singh, P., Azhar, A., Naseem, A., Rashid, Q., Kabir, M. A. & Jairajpuri, M. A. (2011). J. Amino Acids, 2011, 1-10.]). The hinge region is marked with an oval.

The four molecules in the final model differ in the number of modelled amino acids near the P1 site. Chains A and D contain 373 residues, with amino acids Ser342, Leu343 and Val344 missing, compared with chain B, which lacks Ser342 and Leu343 and consists of 374 residues, and chain C, in which only Ser342 is missing and which consists of 375 residues (out of a total of 376 residues). The missing residues were observed as an absence of electron density after the P1 residue Glu341 located at the end of the inserted RCL, now called s4A (Fig. 5[link]). Alignment of the chains using PyMOL (Schrödinger) showed minor differences, which were confirmed by r.m.s.d. calculations between chain C (3014 atoms) and the other three chains: chain A, r.m.s.d. of 0.181 Å (2351 atoms); chain B, r.m.s.d. of 0.270 Å (2424 atoms); chain D, r.m.s.d. of 0.271 Å (2367 atoms).

3.6. Structural differences in native and cleaved Iripin-4

Structural comparison of the native and cleaved conformations of Iripin-4 shows that the β-strands in β-sheet A, together with α-helix D, α-helix E, α-helix F and α-helix I, shift to make space for the inserted RCL (Fig. 5[link]). Since the cleaved conformation of serpin is structurally most related to the structure of the covalent complex between the serpin and the protease, it can be concluded that these structural changes will be the same or at least similar to the changes required for formation of the covalent complex. These observations also show how a significant conformational change is required for transition from the native to the cleaved state and also for protease inhibition. In addition to the structural changes in the shutter and hinge regions, a shift of the gate region, the loop part of β-sheet C between the s3C and s4C strands, is evident (Fig. 5[link]).

The aforementioned breach, shutter, hinge and gate regions are involved in the incorporation of the RCL, specifically the hinge region of the RCL, into β-sheet A through coordinated movements in this complex process (Khan et al., 2011[Khan, M. S., Singh, P., Azhar, A., Naseem, A., Rashid, Q., Kabir, M. A. & Jairajpuri, M. A. (2011). J. Amino Acids, 2011, 1-10.]; Pearce et al., 2007[Pearce, M. C., Pike, R. N., Lesk, A. M. & Bottomley, S. P. (2007). Molecular and Cellular Aspects of the Serpinopathies and Disorders in Serpin Activity, edited by D. A. Silverman & G. A. Lomas, pp. 35-66. Singapore: World Scientific.]). This process is referred to as the S-to-R transition, which involves a transition from a native stressed state to a more relaxed cleaved state with greater thermal stability (Whisstock et al., 2000[Whisstock, J. C., Skinner, R., Carrell, R. W. & Lesk, A. M. (2000). J. Mol. Biol. 296, 685-699.]). Comparison of the native and cleaved structures of Iripin-4 (Fig. 5[link]) shows significant movement in the breach and shutter regions. The breach region, which is the starting point in the inhibitory mechanism, was slightly open compared with other solved structures of native serpins from I. ricinus (Fig. 6[link]) and thus is more flexible than the shutter region, which is responsible for controlling or preventing undesired conformational change. The shutter region has more than 85% conserved residues and must open to incorporate the RCL, which helps to stabilize this transition (Irving et al., 2000[Irving, J. A., Pike, R. N., Lesk, A. M. & Whisstock, J. C. (2000). Genome Res. 10, 1845-1864.]). The polar contacts between s3A and s5A, more precisely Glu316–Asn167, Lys318–Asn167 and Thr319–Ile169, were disrupted by the insertion of the RCL compared with the cleaved structure with the additional β-s4A strand. For proper inhibition of the RCL by the protease, the transition must occur outside the gate region (Khan et al., 2011[Khan, M. S., Singh, P., Azhar, A., Naseem, A., Rashid, Q., Kabir, M. A. & Jairajpuri, M. A. (2011). J. Amino Acids, 2011, 1-10.]) and result in cleavage of the serpin instead of the formation of a covalent complex with the protease.

[Figure 6]
Figure 6
Superposition and alignment of I. ricinus native serpin conformations. (a) Superposition of the Iripin-4 (PDB entry 7zbf), Iripin-1 (PDB entry 7qtz; Chlastáková et al., 2023[Chlastáková, A., Kaščáková, B., Kotál, J., Langhansová, H., Kotsyfakis, M., Kutá Smatanová, I., Tirloni, L. & Chmelař, J. (2023). Front. Immunol. 14, 1116324.]) and Iripin-8 (PDB entry 7pmu) crystal structures displayed as cartoons. The structure models are differentiated as follows: Iripin-4 is in blue, Iripin-1 is in red and Iripin-8 is in green. The structure of Iripin-1 was modified because of the absence of residues in its RCL, which are coloured salmon for emphasis. (b) A closer view of the RCL residues displayed as sticks; the colours are as described previously. (c) Structure-based sequence alignment of I. ricinus native serpins. The secondary-structure elements are depicted as arrows for β-strands and spirals for α-helices. The RCL is highlighted in a black box and the P1 and P1′ residues are marked according to the nomenclature of Schechter & Berger (1967[Schechter, I. & Berger, A. (1967). Biochem. Biophys. Res. Commun. 27, 157-162.]).

4. Discussion

Iripin-4 does not show inhibition by the typical mechanism of enzyme inhibition, i.e. by forming a covalent complex with the tested target protease. The most prevalent residue in the P1 site differs from the arginine residue found in other I. ricinus serpins with known structures, namely Iripin-5, Iripin-8 and Iripin-3 (Arg342 in PDB entry 7b2t, Arg364 in PDB entry 7pmu and Arg357 in PDB entry 7ahp, respectively). The other known I. ricinus serpins contain Glu341 (Iripin-4), Tyr341 (Iripin-2, formerly named IRS-2; PDB entry 3nda) or Met340 (Iris) at the P1 position (Supplementary Fig. S6; Chmelar et al., 2011[Chmelar, J., Oliveira, C. J., Rezacova, P., Francischetti, I. M. B., Kovarova, Z., Pejler, G., Kopacek, P., Ribeiro, J. M. C., Mares, M., Kopecky, J. & Kotsyfakis, M. (2011). Blood, 117, 736-744.]; Kotál et al., 2021[Kotál, J., Polderdijk, S. G. I., Langhansová, H., Ederová, M., Martins, L. A., Beránková, Z., Chlastáková, A., Hajdušek, O., Kotsyfakis, M., Huntington, J. A. & Chmelař, J. (2021). Int. J. Mol. Sci. 22, 9480.]; Chlastáková et al., 2021[Chlastáková, A., Kotál, J., Beránková, Z., Kaščáková, B., Martins, L. A., Langhansová, H., Prudnikova, T., Ederová, M., Kutá Smatanová, I., Kotsyfakis, M. & Chmelař, J. (2021). Front. Immunol. 12, 626200.]; Kascakova et al., 2021[Kascakova, B., Kotal, J., Martins, L. A., Berankova, Z., Langhansova, H., Calvo, E., Crossley, J. A., Havlickova, P., Dycka, F., Prudnikova, T., Kuty, M., Kotsyfakis, M., Chmelar, J. & Kuta Smatanova, I. (2021). Acta Cryst. D77, 1183-1196.]; Prevot et al., 2006[Prevot, P.-P., Adam, B., Boudjeltia, K. Z., Brossard, M., Lins, L., Cauchie, P., Brasseur, R., Vanhaeverbeek, M., Vanhamme, L. & Godfroid, E. (2006). J. Biol. Chem. 281, 26361-26369.]). The first serpin characterized in I. ricinus saliva was the immunosuppressant Iris, which inhibits elastase-like proteases. Iris prevents blood clotting by inhibiting factor Xa and thrombin, delays fibrinolysis by inhibiting elastase and tPA, and inhibits the secretion of pro-inflammatory cytokines such as IFNγ and IL-6. Some of these activities are the result of several Iris exosites in the αA and αD areas (Leboulle et al., 2002[Leboulle, G., Rochez, C., Louahed, J., Ruti, B., Brossard, M., Bollen, A. & Godfroid, E. (2002). Am. J. Trop. Med. Hyg. 66, 225-233.]; Prevot et al., 2006[Prevot, P.-P., Adam, B., Boudjeltia, K. Z., Brossard, M., Lins, L., Cauchie, P., Brasseur, R., Vanhaeverbeek, M., Vanhamme, L. & Godfroid, E. (2006). J. Biol. Chem. 281, 26361-26369.], 2009[Prevot, P.-P., Beschin, A., Lins, L., Beaufays, J., Grosjean, A., Bruys, L., Adam, B., Brossard, M., Brasseur, R., Zouaoui Boudjeltia, K., Vanhamme, L. & Godfroid, E. (2009). FEBS J. 276, 3235-3246.]). Another well described serpin from the same tick species is Iripin-2, which targets chymotrypsin-like proteases. Iripin-2 inhibits the pro-inflammatory proteinases cathepsin G and mast-cell chymase. By inhibiting thrombin, Iripin-2 blocks platelet aggregation and has been shown to act as an immunomodulator by inhibiting IL-6 production via altering STAT3 signalling (Chmelar et al., 2011[Chmelar, J., Oliveira, C. J., Rezacova, P., Francischetti, I. M. B., Kovarova, Z., Pejler, G., Kopacek, P., Ribeiro, J. M. C., Mares, M., Kopecky, J. & Kotsyfakis, M. (2011). Blood, 117, 736-744.]; Páleníková et al., 2015[Páleníková, J., Lieskovská, J., Langhansová, H., Kotsyfakis, M., Chmelař, J. & Kopecký, J. (2015). Infect. Immun. 83, 1949-1956.]). Another serpin from I. ricinus, Iripin-3, inhibits trypsin-like proteases, with the highest rates of inhibition against kallikrein and matriptase, and has been shown to suppress inflammation and wound healing. Iripin-3 also suppresses the proliferation and differentiation of CD4+ T cells into a Th1 pro-inflammatory subpopulation, thus regulating adaptive and acquired immune responses (Chlastáková et al., 2021[Chlastáková, A., Kotál, J., Beránková, Z., Kaščáková, B., Martins, L. A., Langhansová, H., Prudnikova, T., Ederová, M., Kutá Smatanová, I., Kotsyfakis, M. & Chmelař, J. (2021). Front. Immunol. 12, 626200.]). Iripin-5, the most abundant salivary serpin in I. ricinus, displays an anti-inflammatory role as it inhibits neutrophil migration and complement activity and suppresses the ability of macrophages to produce NO (Kascakova et al., 2021[Kascakova, B., Kotal, J., Martins, L. A., Berankova, Z., Langhansova, H., Calvo, E., Crossley, J. A., Havlickova, P., Dycka, F., Prudnikova, T., Kuty, M., Kotsyfakis, M., Chmelar, J. & Kuta Smatanova, I. (2021). Acta Cryst. D77, 1183-1196.]). Iripin-8 is an inhibitor of multiple coagulation proteases and strongly inhibits the intrinsic pathway of coagulation. In addition, it inhibits complement-related erythrocyte lysis. Thus, Iripin-8 functions as an anti­coagulant and inhibitor of the complement system (Kotál et al., 2021[Kotál, J., Polderdijk, S. G. I., Langhansová, H., Ederová, M., Martins, L. A., Beránková, Z., Chlastáková, A., Hajdušek, O., Kotsyfakis, M., Huntington, J. A. & Chmelař, J. (2021). Int. J. Mol. Sci. 22, 9480.]). The presence of a partially inserted RCL in Iripin-4 may have led to the observed low inhibition of proteases. This was observed for antithrombin, which had a P1 site that was inaccessible to the target protease in this state. However, it is likely that Iripin-4 targets granzyme B, but weakly. The glutamate at the P1 site indicated that the target is granzyme B. As more functional analyses are needed, exosite-mediated activity similar to Iris cannot be ruled out. Further studies should address the precise function of Iripin-4.

Over the years of crystallographic study of serpins, many structural conformations and states have been identified and the importance of certain structural regions such as the breach, shutter and hinge regions have been described (Dunstone & Whisstock, 2011[Dunstone, M. A. & Whisstock, J. C. (2011). Methods Enzymol. 501, 63-87.]). The only serpin conformation with inhibitory function is the native conformation, which is metastable and stressed (Pearce et al., 2007[Pearce, M. C., Pike, R. N., Lesk, A. M. & Bottomley, S. P. (2007). Molecular and Cellular Aspects of the Serpinopathies and Disorders in Serpin Activity, edited by D. A. Silverman & G. A. Lomas, pp. 35-66. Singapore: World Scientific.]). This type of conformation has been solved for Iripin-4 at 2.3 Å resolution and represents an active serpin ready to `trap' the target protease. The breach region of native Iripin-4 differs from those of other solved native I. ricinus serpin structures (Fig. 6[link]). This is primarily due to the fact that the native structures of Iripin-1 (PDB entry 7qtz; Chlastáková et al., 2023[Chlastáková, A., Kaščáková, B., Kotál, J., Langhansová, H., Kotsyfakis, M., Kutá Smatanová, I., Tirloni, L. & Chmelař, J. (2023). Front. Immunol. 14, 1116324.]) and Iripin-8 (PDB entry 7pmu; Kotál et al., 2021[Kotál, J., Polderdijk, S. G. I., Langhansová, H., Ederová, M., Martins, L. A., Beránková, Z., Chlastáková, A., Hajdušek, O., Kotsyfakis, M., Huntington, J. A. & Chmelař, J. (2021). Int. J. Mol. Sci. 22, 9480.]) were solved in the fully stressed state, as opposed to Iripin-4, which was solved in the partially relaxed state (Fig. 6[link]). The breach region, which is located at the top of the s3A and s5A β-strands of β-sheet A, is opened laterally mainly by moving s3A to the site to create space for partial insertion of the RCL. In contrast, Iripin-1 and Iripin-8 do not have this gap in the breach region (Fig. 6[link]). The shutter region (the middle part of β-sheet A) of all three serpins is almost identical. Another region that is part of the RCL (P15–P9), the hinge region, differs structurally between the three serpins because this region is responsible for the mobility of the RCL and its insertion into β-sheet A (Hopkins et al., 1993[Hopkins, P. C. R., Carrell, R. W. & Stone, S. R. (1993). Biochemistry, 32, 7650-7657.]; Sanrattana et al., 2019[Sanrattana, W., Maas, C. & de Maat, S. (2019). Front. Med. 6, 25.]). The hinge regions also differ in sequence: while Iripin-4 has threonine at the P14 site and glycine at the P10 site, Iripin-1 and Iripin-8 have serine at the P14 site and alanine at the P10 site. However, this does not suggest any functional difference, as it has been shown that uncharged residues are suitable for loop insertion but do not affect the protease selectivity (Lawrence et al., 2000[Lawrence, D. A., Olson, S. T., Muhammad, S., Day, D. E., Kvassman, J., Ginsburg, D. & Shore, J. D. (2000). J. Biol. Chem. 275, 5839-5844.]). It has been suggested that the use of cofactors during crystallization can lead to a fully exposed RCL state by stabilizing the hinge region (Whisstock & Bottomley, 2006[Whisstock, J. C. & Bottomley, S. P. (2006). Curr. Opin. Struct. Biol. 16, 761-768.]; Li et al., 2004[Li, W., Johnson, D. J. D., Esmon, C. T. & Huntington, J. A. (2004). Nat. Struct. Mol. Biol. 11, 857-862.]), but this has not been observed for the mentioned proteins. The most remarkable part of native I. ricinus serpins is the length of the RCL, specifically the Iripin-8 RCL, which is longer by five residues. Another difference is that Iripin-4 has a P1 glutamate in its recognition site, whereas Iripin-1 and Iripin-8 have an arginine. Glutamate residues located at P4′ and P5′ have been reported to increase the rate of serpin inhibition (Ibarra et al., 2004[Ibarra, C. A., Blouse, G. E., Christian, T. D. & Shore, J. D. (2004). J. Biol. Chem. 279, 3643-3650.]). The r.m.s.d. between molecules was calculated using PyMOL (Schrödinger) and the results showed that the r.m.s.d. on alignment of Iripin-4 with the Iripin-1 model was 0.894 Å (2008 atoms) and that with Iripin-8 was 1.143 Å (1943 atoms). Iripin-8 inhibits serine proteases involved in coagulation and complement functions. These proteases include thrombin, factor Xa, factor XIa, factor VIIa, factor IXa, kallikrein and plasmin (Kotál et al., 2021[Kotál, J., Polderdijk, S. G. I., Langhansová, H., Ederová, M., Martins, L. A., Beránková, Z., Chlastáková, A., Hajdušek, O., Kotsyfakis, M., Huntington, J. A. & Chmelař, J. (2021). Int. J. Mol. Sci. 22, 9480.]). In contrast, Iripin-4 shows no significant inhibition of the tested proteases.

Comparison of cleaved I. ricinus structures, specifically Iripin-2 (PDB entry 3nda; Kovářová et al., 2010[Kovářová, Z., Chmelař, J., Šanda, M., Brynda, J., Mareš, M. & Řezáčová, P. (2010). Acta Cryst. F66, 1453-1457.]), Iripin-3 (PDB entry 7ahp; Chlastáková et al., 2021[Chlastáková, A., Kotál, J., Beránková, Z., Kaščáková, B., Martins, L. A., Langhansová, H., Prudnikova, T., Ederová, M., Kutá Smatanová, I., Kotsyfakis, M. & Chmelař, J. (2021). Front. Immunol. 12, 626200.]) and Iripin-5 (PDB entry 7b2t; Prevot et al., 2006[Prevot, P.-P., Adam, B., Boudjeltia, K. Z., Brossard, M., Lins, L., Cauchie, P., Brasseur, R., Vanhaeverbeek, M., Vanhamme, L. & Godfroid, E. (2006). J. Biol. Chem. 281, 26361-26369.]), with the cleaved structure of Iripin-4 showed almost identical structural folding (Fig. 7[link]). The results of alignment calculations showed that the r.m.s.d. on alignment of Iripin-4 with Iripin-2 is 0.750 Å (2212 atoms), that with Iripin-3 is 0.525 Å (2090 atoms) and that with Iripin-5 is 0.690 Å (2132 atoms). The differences are mainly in loop regions and mainly in the αD helix.

[Figure 7]
Figure 7
Superposition and alignment of I. ricinus cleaved serpin conformations. (a) Superposition of the Iripin-4 (PDB entry 7zas), Iripin-2 (PDB entry 3nda), Iripin-3 (PDB entry 7ahp) and Iripin-5 (PDB entry 7b2t) crystal structures displayed as cartoons. The structure models are differentiated as follows: Iripin-4 is in blue, Iripin-2 is in grey, Iripin-3 is in magenta and Iripin-5 is in cyan. The RCL of all serpins is coloured salmon. (b) Structure-based sequence alignment of I. ricinus cleaved serpins. The secondary-structure elements are marked with arrows for β-strands and spirals for α-helices. The inserted RCL is highlighted in the black box and the P1 and P1′ residues are marked according to the nomenclature of Schechter & Berger (1967[Schechter, I. & Berger, A. (1967). Biochem. Biophys. Res. Commun. 27, 157-162.]).

5. Conclusions

In conclusion, we have been able to define two structurally distinct steps in the likely mechanism of protease inhibition by Iripin-4. However, Iripin-4 was shown to inhibit only granzyme B protease, as no other protease tested was confirmed to be inhibited. Iripin-4 has also been shown to serve as a substrate for porcine elastase. The inhibition of granzyme B can be explained by the presence of Glu341 at the P1 site, which should indicate that Iripin-4 should be a potent inhibitor of this protease. However, Iripin-4 did not exhibit potent inhibition against granzyme B. Since the native structure was solved in a partially relaxed state, this cannot be ruled out as one of the reasons for the observed weak inhibition rate, although it may still be only an artefact of crystallization. In addition, it can be hypothesized that Iripin-4 may use a mechanism of inhibition other than the typical one or that some cofactors are required to increase the activity of this inhibitor. Further activity studies are needed to confirm the exact function of this serpin during the tick-feeding process.

Supporting information


Acknowledgements

We thank Helmholtz-Zentrum Berlin (HZB) for the allocation of synchrotron-radiation beamtime during which the diffraction data were collected (BL14.1, BESSY II electron-storage ring). The authors declare no conflicts of interest. Author contributions were as follows. IKS and JC designed the project. JK performed the cloning, expression and purification and determined the antiprotease selectivity. BK and VV cloned, expressed and purified the mutants of Iripin-4 and determined the antiprotease selectivity. BK, PH, PG, MK and TP carried out crystallization experiments and performed X-ray diffraction analysis. BK analysed the crystallographic data, solved the structures and drafted the manuscript.

Funding information

The following funding is acknowledged: European Regional Development Fund (grant No. CZ.02.1.01/0.0/0.0/15_003/0000441); The Grant Agency of the Czech Republic (grant No. 19-14704Y); The Grant Agency of the University of South Bohemia (grant No. 04-046/2022/P).

References

First citationBoulanger, N., Boyer, P., Talagrand-Reboul, E. & Hansmann, Y. (2019). Med. Mal. Infect. 49, 87–97.  CrossRef CAS PubMed Google Scholar
First citationChen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationChlastáková, A., Kaščáková, B., Kotál, J., Langhansová, H., Kotsyfakis, M., Kutá Smatanová, I., Tirloni, L. & Chmelař, J. (2023). Front. Immunol. 14, 1116324.  PubMed Google Scholar
First citationChlastáková, A., Kotál, J., Beránková, Z., Kaščáková, B., Martins, L. A., Langhansová, H., Prudnikova, T., Ederová, M., Kutá Smatanová, I., Kotsyfakis, M. & Chmelař, J. (2021). Front. Immunol. 12, 626200.  Web of Science PubMed Google Scholar
First citationChmelar, J., Oliveira, C. J., Rezacova, P., Francischetti, I. M. B., Kovarova, Z., Pejler, G., Kopacek, P., Ribeiro, J. M. C., Mares, M., Kopecky, J. & Kotsyfakis, M. (2011). Blood, 117, 736–744.  Web of Science CrossRef CAS PubMed Google Scholar
First citationDunstone, M. A. & Whisstock, J. C. (2011). Methods Enzymol. 501, 63–87.  Web of Science CrossRef CAS PubMed Google Scholar
First citationEmsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationFuente, J. de la, Kopáček, P., Lew-Tabor, A. & Maritz-Olivier, C. (2016). Parasite Immunol. 38, 754–769.  PubMed Google Scholar
First citationGarzón-Tituaña, M., Arias, M. A., Sierra-Monzón, J. L., Morte-Romea, E., Santiago, L., Ramirez-Labrada, A., Martinez-Lostao, L., Paño-Pardo, J. R., Galvez, E. M. & Pardo, J. (2020). Front. Immunol. 11, 1054.  PubMed Google Scholar
First citationGettins, P. G. W. (2002). Chem. Rev. 102, 4751–4804.  Web of Science CrossRef PubMed CAS Google Scholar
First citationHopkins, P. C. R., Carrell, R. W. & Stone, S. R. (1993). Biochemistry, 32, 7650–7657.  CrossRef CAS PubMed Google Scholar
First citationHuntington, J. A. (2011). J. Thromb. Haemost. 9, 26–34.  Web of Science CrossRef CAS PubMed Google Scholar
First citationHuntington, J. A. & Carrell, R. W. (2001). Sci. Prog. 84, 125–136.  CrossRef PubMed CAS Google Scholar
First citationIbarra, C. A., Blouse, G. E., Christian, T. D. & Shore, J. D. (2004). J. Biol. Chem. 279, 3643–3650.  CrossRef PubMed CAS Google Scholar
First citationIrving, J. A., Miranda, E., Haq, I., Perez, J., Kotov, V. R., Faull, S., Motamedi-Shad, N. & Lomas, D. A. (2015). Biochem. J. 468, 99–108.  CrossRef CAS PubMed Google Scholar
First citationIrving, J. A., Pike, R. N., Lesk, A. M. & Whisstock, J. C. (2000). Genome Res. 10, 1845–1864.  Web of Science CrossRef PubMed CAS Google Scholar
First citationKabsch, W. (2010). Acta Cryst. D66, 125–132.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationKaiserman, D., Whisstock, J. C. & Bird, P. I. (2006). Expert Rev. Mol. Med. 8, 1–19.  CrossRef PubMed Google Scholar
First citationKascakova, B., Kotal, J., Martins, L. A., Berankova, Z., Langhansova, H., Calvo, E., Crossley, J. A., Havlickova, P., Dycka, F., Prudnikova, T., Kuty, M., Kotsyfakis, M., Chmelar, J. & Kuta Smatanova, I. (2021). Acta Cryst. D77, 1183–1196.  CrossRef IUCr Journals Google Scholar
First citationKhan, M. S., Singh, P., Azhar, A., Naseem, A., Rashid, Q., Kabir, M. A. & Jairajpuri, M. A. (2011). J. Amino Acids, 2011, 1–10.  CrossRef CAS Google Scholar
First citationKomiyama, T., Ray, C. A., Pickup, D. J., Howard, A. D., Thornberry, N. A., Peterson, E. P. & Salvesen, G. (1994). J. Biol. Chem. 269, 19331–19337.  CrossRef CAS PubMed Google Scholar
First citationKotál, J., Polderdijk, S. G. I., Langhansová, H., Ederová, M., Martins, L. A., Beránková, Z., Chlastáková, A., Hajdušek, O., Kotsyfakis, M., Huntington, J. A. & Chmelař, J. (2021). Int. J. Mol. Sci. 22, 9480.  PubMed Google Scholar
First citationKovářová, Z., Chmelař, J., Šanda, M., Brynda, J., Mareš, M. & Řezáčová, P. (2010). Acta Cryst. F66, 1453–1457.  Web of Science CrossRef IUCr Journals Google Scholar
First citationKrissinel, E., Uski, V., Lebedev, A., Winn, M. & Ballard, C. (2018). Acta Cryst. D74, 143–151.  Web of Science CrossRef IUCr Journals Google Scholar
First citationLawrence, D. A., Olson, S. T., Muhammad, S., Day, D. E., Kvassman, J., Ginsburg, D. & Shore, J. D. (2000). J. Biol. Chem. 275, 5839–5844.  CrossRef PubMed CAS Google Scholar
First citationLeboulle, G., Rochez, C., Louahed, J., Ruti, B., Brossard, M., Bollen, A. & Godfroid, E. (2002). Am. J. Trop. Med. Hyg. 66, 225–233.  CrossRef PubMed CAS Google Scholar
First citationLi, W., Johnson, D. J. D., Esmon, C. T. & Huntington, J. A. (2004). Nat. Struct. Mol. Biol. 11, 857–862.  CrossRef PubMed CAS Google Scholar
First citationLong, F., Vagin, A. A., Young, P. & Murshudov, G. N. (2008). Acta Cryst. D64, 125–132.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationMadison-Antenucci, S., Kramer, L. D., Gebhardt, L. L. & Kauffman, E. (2020). Clin. Microbiol. Rev. 33, e00083-18.  CAS PubMed Google Scholar
First citationMcNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. M. (2011). Acta Cryst. D67, 386–394.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationMeekins, D. A., Kanost, M. R. & Michel, K. (2017). Semin. Cell Dev. Biol. 62, 105–119.  CrossRef CAS PubMed Google Scholar
First citationMueller, U., Förster, R., Hellmig, M., Huschmann, F. U., Kastner, A., Malecki, P., Pühringer, S., Röwer, M., Sparta, K., Steffien, M., Ühlein, M., Wilk, P. & Weiss, M. S. (2015). Eur. Phys. J. Plus, 130, 141.  Web of Science CrossRef Google Scholar
First citationMurshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationPáleníková, J., Lieskovská, J., Langhansová, H., Kotsyfakis, M., Chmelař, J. & Kopecký, J. (2015). Infect. Immun. 83, 1949–1956.  Web of Science PubMed Google Scholar
First citationPearce, M. C., Pike, R. N., Lesk, A. M. & Bottomley, S. P. (2007). Molecular and Cellular Aspects of the Serpinopathies and Disorders in Serpin Activity, edited by D. A. Silverman & G. A. Lomas, pp. 35–66. Singapore: World Scientific.  Google Scholar
First citationPrevot, P.-P., Adam, B., Boudjeltia, K. Z., Brossard, M., Lins, L., Cauchie, P., Brasseur, R., Vanhaeverbeek, M., Vanhamme, L. & Godfroid, E. (2006). J. Biol. Chem. 281, 26361–26369.  Web of Science CrossRef PubMed CAS Google Scholar
First citationPrevot, P.-P., Beschin, A., Lins, L., Beaufays, J., Grosjean, A., Bruys, L., Adam, B., Brossard, M., Brasseur, R., Zouaoui Boudjeltia, K., Vanhamme, L. & Godfroid, E. (2009). FEBS J. 276, 3235–3246.  Web of Science CrossRef PubMed CAS Google Scholar
First citationPrevot, P.-P., Couvreur, B., Denis, V., Brossard, M., Vanhamme, L. & Godfroid, E. (2007). Vaccine, 25, 3284–3292.  Web of Science CrossRef PubMed CAS Google Scholar
First citationRizzoli, A., Hauffe, H. C., Carpi, G., Vourc'h, G. I., Neteler, M. & Rosà, R. (2011). Euro Surveill. 16, 19906.  CrossRef PubMed Google Scholar
First citationRosario-Cruz, R., Almazan, C., Miller, R. J., Dominguez-Garcia, D. I., Hernandez-Ortiz, R. & de La Fuente, J. (2009). Front. Biosci. 14, 2657–2665.  CAS Google Scholar
First citationSanrattana, W., Maas, C. & de Maat, S. (2019). Front. Med. 6, 25.  CrossRef Google Scholar
First citationSchechter, I. & Berger, A. (1967). Biochem. Biophys. Res. Commun. 27, 157–162.  CrossRef CAS PubMed Web of Science Google Scholar
First citationSchwarz, A., von Reumont, B. M., Erhart, J., Chagas, A. C., Ribeiro, J. M. C. & Kotsyfakis, M. (2013). FASEB J. 27, 4745–4756.  CrossRef CAS PubMed Google Scholar
First citationSilverman, G. A., Whisstock, J. C., Bottomley, S. P., Huntington, J. A., Kaiserman, D., Luke, C. J., Pak, S. C., Reichhart, J. M. & Bird, P. I. (2010). J. Biol. Chem. 285, 24299–24305.  Web of Science CrossRef CAS PubMed Google Scholar
First citationSparta, K. M., Krug, M., Heinemann, U., Mueller, U. & Weiss, M. S. (2016). J. Appl. Cryst. 49, 1085–1092.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationSpence, M. A., Mortimer, M. D., Buckle, A. M., Minh, B. Q. & Jackson, C. J. (2021). Mol. Biol. Evol. 38, 2915–2929.  Web of Science CrossRef CAS PubMed Google Scholar
First citationVagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationVercammen, D., Belenghi, B., van de Cotte, B., Beunens, T., Gavigan, J.-A., De Rycke, R., Brackenier, A., Inzé, D., Harris, J. L. & Van Breusegem, F. (2006). J. Mol. Biol. 364, 625–636.  CrossRef PubMed CAS Google Scholar
First citationWhisstock, J., Skinner, R. & Lesk, A. M. (1998). Trends Biochem. Sci. 23, 63–67.  Web of Science CrossRef CAS PubMed Google Scholar
First citationWhisstock, J. C. & Bottomley, S. P. (2006). Curr. Opin. Struct. Biol. 16, 761–768.  Web of Science CrossRef PubMed CAS Google Scholar
First citationWhisstock, J. C., Silverman, G. A., Bird, P. I., Bottomley, S. P., Kaiserman, D., Luke, C. J., Pak, S. C., Reichhart, J. M. & Huntington, J. A. (2010). J. Biol. Chem. 285, 24307–24312.  Web of Science CrossRef CAS PubMed Google Scholar
First citationWhisstock, J. C., Skinner, R., Carrell, R. W. & Lesk, A. M. (2000). J. Mol. Biol. 296, 685–699.  Web of Science CrossRef PubMed CAS Google Scholar
First citationWinn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson, K. S. (2011). Acta Cryst. D67, 235–242.  Web of Science CrossRef CAS IUCr Journals Google Scholar
First citationYoung, J. Y., Westbrook, J. D., Feng, Z., Sala, R., Peisach, E., Oldfield, T. J., Sen, S., Gutmanas, A., Armstrong, D. R., Berrisford, J. M., Chen, L., Chen, M., Di Costanzo, L., Dimitropoulos, D., Gao, G., Ghosh, S., Gore, S., Guranovic, V., Hendrickx, P. M. S., Hudson, B. P., Igarashi, R., Ikegawa, Y., Kobayashi, N., Lawson, C. L., Liang, Y., Mading, S., Mak, L., Mir, M. S., Mukhopadhyay, A., Patwardhan, A., Persikova, I., Rinaldi, L., Sanz-Garcia, E., Sekharan, M. R., Shao, C., Swaminathan, G. J., Tan, L., Ulrich, E. L., van Ginkel, G., Yamashita, R., Yang, H., Zhuravleva, M. A., Quesada, M., Kleywegt, G. J., Berman, H. M., Markley, J. L., Nakamura, H., Velankar, S. & Burley, S. K. (2017). Structure, 25, 536–545.  Web of Science CrossRef CAS PubMed Google Scholar

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.

Journal logoSTRUCTURAL
BIOLOGY
ISSN: 2059-7983
Follow Acta Cryst. D
Sign up for e-alerts
Follow Acta Cryst. on Twitter
Follow us on facebook
Sign up for RSS feeds